Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.

The user is using topical finasteride 0.3% and minoxidil 5% for hair regrowth, along with dermal stamping, zinc, fish oils, and biotin. They report some regrowth and shedding, with no significant side effects.

The user received 1600 hair grafts but is dissatisfied and plans a second transplant for better coverage. They use minoxidil and finasteride and are considering adding dutasteride.

Minoxidil and finasteride are discussed for hair loss, with concerns about minoxidil's heart-related side effects. New treatments like PP405 are met with skepticism, often humorously noted as always being "five years away."

A user switched from topical to oral finasteride and is seeking additional topical treatments for hair growth besides minoxidil. They are aware of stemoxydine and caffeine solutions and are asking for more recommendations.

Dutasteride capsules should not be bitten or opened due to their foul taste and potential caustic effects. Users shared experiences of accidentally biting capsules and the unpleasant taste, with some suggesting swallowing techniques to avoid this.

The user shared their 5-month progress using oral finasteride, topical minoxidil, and weekly dermarolling for hair loss. They expressed pride in their results, receiving positive feedback from others.

The user aims to achieve a hypertrichosis look and has used topical Minoxidil for 20 years, now trying oral Minoxidil in a low dose. They seek alternatives to Minoxidil to avoid side effects.

A user shared their experience with oral minoxidil and finasteride for hair loss, taking 7.5mg of minoxidil and experiencing excessive hair growth all over their body without major side effects. Some users suggested lower doses for safety, while others shared their own experiences with hair growth in different areas and side effects.

A humorous discussion about hair regrowth using finasteride, with jokes about telekinesis and tiny ants. The conversation is satirical, with users making light of hair loss treatments.

User used topical fin/min 3-4 times a week for 6 months, showing hairline improvement. Others praised progress and discussed haircuts.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

A user's journey with hair loss and their use of topical finasteride, minoxidil and pyri/minoxidil ratio treatments to attempt hair regrowth. Replies focused on offering support and advice while sharing personal experiences with different treatments.

User experienced hair kinking after starting minoxidil, despite being on finasteride for two years. Another user confirmed similar issues and suggested switching brands due to propylene glycol in minoxidil.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.

Scube3 trials have not started yet. Treatments discussed include Minoxidil, finasteride, and RU58841.

The user is applying topical finasteride with stemoxydine for hair loss and has noticed hair thickening but no regrowth after two months. They also report high SHBG and prolactin levels and a lack of morning erections, even on low doses of medication.

Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to be overharvested without noticeable hair loss. The conversation questions if this method is practiced in clinics or if it's theoretical, and whether it relates to hair cloning or multiplication.

Peptides, specifically GHK-Cu, are being considered for hair growth benefits, such as increasing blood flow to the scalp and preventing hair follicle shrinkage. A user reported starting GHK-Cu after hearing it made a friend's hair thicker.

FLEAVA is accused of scamming customers by enrolling them in unwanted monthly subscriptions for Advanced Copper Peptide without consent. Many users struggled to get refunds and reported ongoing charges despite cancellation requests.

A user applied a homemade topical finasteride solution daily for 35 days, reducing hair shedding significantly with minimal side effects. They plan to continue for 90 days and will provide further updates.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. PP405 is still under evaluation for safety.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

A 24-year-old is seeking advice on whether to get a hair transplant now or wait until age 25, and is asking for clinic recommendations in Puglia, Brindisi, Albania, Türkiye, or Naples.

A user shared a 7-month update on hair regrowth using finasteride daily and minoxidil once a day, noting improvement in hair health. Others suggested adding micro-needling, ketoconazole shampoo, and considering a hair transplant for better results.

The conversation is about hair regrowth using topical finasteride, minoxidil, and keto spray, along with oral Saw Palmetto, Lustriva complex, collagen, and microneedling. Users discuss their experiences with these treatments, noting improvements in hair density and color, with some experiencing mild side effects.

Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.

The user shared progress photos of hair regrowth using copper peptides and NAD+ over five months. Another user commented on the lighting, and another praised the progress.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.